View Item 

Show simple item record

The impact of recent vincristine on human hematopoietic progenitor cell collection in pediatric patients with central nervous system tumors

dc.contributor.authorCooling, Lauraen_US
dc.contributor.authorBombery, Melissaen_US
dc.contributor.authorHoffmann, Sandraen_US
dc.contributor.authorDavenport, Robertsonen_US
dc.contributor.authorRobertson, Patriciaen_US
dc.contributor.authorLevine, John E.en_US
dc.date.accessioned2014-09-03T16:52:18Z
dc.date.availableWITHHELD_12_MONTHSen_US
dc.date.available2014-09-03T16:52:18Z
dc.date.issued2014-08en_US
dc.identifier.citationCooling, Laura; Bombery, Melissa; Hoffmann, Sandra; Davenport, Robertson; Robertson, Patricia; Levine, John E. (2014). "The impact of recent vincristine on human hematopoietic progenitor cell collection in pediatric patients with central nervous system tumors." Transfusion (8): 2004-2014.en_US
dc.identifier.issn0041-1132en_US
dc.identifier.issn1537-2995en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/108370
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherAmerican Association of Blood Banksen_US
dc.titleThe impact of recent vincristine on human hematopoietic progenitor cell collection in pediatric patients with central nervous system tumorsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108370/1/trf12574.pdf
dc.identifier.doi10.1111/trf.12574en_US
dc.identifier.sourceTransfusionen_US
dc.identifier.citedreferencePerseghin P, Balduzzi A, Bonanomi S, et al. Infusion‐related side‐effects in children undergoing autologous hematopoietic stem cell transplantation for acute leukemia. Bone Marrow Transplant 2000; 26: 116 ‐ 118.en_US
dc.identifier.citedreferenceFood and Drug Administration. Code of Federal Regulations, General Biological Product Standards: 21 CFR 610.12. 2011.en_US
dc.identifier.citedreferenceJakacki R, Burger P, Zhou T, et al. Outcome for metastatic (M+) medulloblastoma treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide and vincristine: preliminary result of COG 99701 [abstract]. J Clin Oncol 2007; 25: 2017.en_US
dc.identifier.citedreferenceCoughlin DT, Richmond RC. Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials and the emergence of carboplatin. Semin Oncol 1989; 16: 31 ‐ 43.en_US
dc.identifier.citedreferenceCooling L, Gorlin JB. Transfusion reactions associated with hematopoietic progenitor cell reinfusion. In: Poposvsky MA, editor. Transfusion reactions. 3rd ed. Bethseda, MD: American Association of Blood Banks; 2007. p. 301 ‐ 330.en_US
dc.identifier.citedreferenceOkamoto Y, Takaue Y, Saito S, et al. Toxicities associated with cryopreserved and thawed peripheral blood stem cell autografts in children with active cancer. Transfusion 1993; 33: 578 ‐ 581.en_US
dc.identifier.citedreferenceCalmels B, Lemarie C, Esterni B, et al. Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. Transfusion 2007; 47: 1268 ‐ 1275.en_US
dc.identifier.citedreferenceSchulmeister L. Preventing vincristine sulfate medication errors. Oncol Nurs Forum 2004; 31: E90 ‐ 96.en_US
dc.identifier.citedreferenceTrinkle R, Wu JK. Errors involving pediatric patients receiving chemotherapy: a literature review. Med Pediatr Oncol 1996; 26: 344 ‐ 351.en_US
dc.identifier.citedreferencePearson AD, Pinkerton CR, Lewis IJ, et al. High‐dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomized trial. Lancet Oncol 2008; 9: 247 ‐ 256.en_US
dc.identifier.citedreferenceKletzel M, Katzenstein HM, Haut PR, et al. Treatment of high‐risk neuroblastoma with triple‐tandem high‐dose therapy and stem cell rescue: results of the Chicago pilot II study. J Clin Oncol 2002; 20: 2284 ‐ 2292.en_US
dc.identifier.citedreferenceSchroeder H, Kamperis K, Grunnet N, et al. Prediction of target CD34 positive cells following leukopheresis in children with neuroblastoma. Pediatr Blood Cancer 2006; 46: 786 ‐ 792.en_US
dc.identifier.citedreferenceBensimhon P, Villablanca JG, Sender LS, et al. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. Pediatr Blood Cancer 2010; 54: 596 ‐ 602.en_US
dc.identifier.citedreferenceBalduzzi A, Perseghin P, Dassi M, et al. Peripheral blood stem cell collection in children with acute leukemia: effectiveness of the ‘DIAVE’ mobilizing regimen. Bone Marrow Transplant 2002; 30: 413 ‐ 416.en_US
dc.identifier.citedreferenceZeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the children's cancer group 921 randomized phase III study. J Clin Oncol 1999; 17: 832 ‐ 845.en_US
dc.identifier.citedreferenceKapoor N, Keever CA, Leong N, et al. Effects of ex vivo treatment with methylprednisolone and vincristine on bone marrow lymphohematopoietic cells. In: Worthington‐White DA, Gee AP, Gross S, editors. Progress in clinical and biological research, Vol. 377: Advances in bone marrow purging and processing. New York: Wiley‐Liss; 1992. p. 49 ‐ 56.en_US
dc.identifier.citedreferenceLanfranchi A, Andolina M, Tettoni K, et al. Functional depletion of T cells by vincristine and methylprednisolone as an invitro model for the prevention of graft versus host disease. Haematologica 1992; 77: 11 ‐ 15.en_US
dc.identifier.citedreferenceNecas E, Ponka P, Neuwirt J. Effect of some cytostatics on the haemopoietic stem cells (CFUs) in blood. Cancer Chemother Pharmacol 1979; 2: 215 ‐ 219.en_US
dc.identifier.citedreferenceJones RJ, Miller CB, Zehnbauer BA, et al. In vitro evaluation of combination drug purging for autologous bone marrow transplantation. Bone Marrow Transplant 1990; 5: 301 ‐ 307.en_US
dc.identifier.citedreferenceRowley SD, Miller CB, Piantadosi S, et al. Phase I study of combination drug purging for autologous bone marrow transplantation. J Clin Oncol 1991; 9: 2210 ‐ 2218.en_US
dc.identifier.citedreferenceCentral Brain Tumor Registry of the United States (CBTRUS). CBTRUS statistical report. Primary brain and central nervous system tumors diagnosed in the United States in 2004–2008 (revised March 23, 2012). [cited 2012 Jun 20]. Available from: http://www.cbtrus.org/2012‐NPCR‐SEER/CBTRUS_Report_2004‐2008_3‐23‐2012.pdfen_US
dc.identifier.citedreferenceMassimino M, Giangaspero F, Garre ML, et al. Childhood medulloblastoma. Crit Rev Oncol Hematol 2011; 79: 65 ‐ 83.en_US
dc.identifier.citedreferenceVaran A. Risk‐adapted chemotherapy in childhood medulloblastoma. Expert Rev Anticancer Ther 2011; 11: 771 ‐ 780.en_US
dc.identifier.citedreferenceWright KD, Gajjar A. New chemotherapy strategies and biological agents in the treatment of childhood ependymoma. Childs Nerv Syst 2009; 25: 1275 ‐ 1282.en_US
dc.identifier.citedreferenceBourdeaut F, Miquel C, Alapetite C, et al. Medulloblastomas: update on a heterogenous disease. Curr Opin Oncol 2011; 23: 630 ‐ 637.en_US
dc.identifier.citedreferenceGrill J, Bergthold G, Ferreira C. Pediatric ependymomas: will molecular biology change patient management? Curr Opin Oncol 2011; 23: 638 ‐ 642.en_US
dc.identifier.citedreferenceHilden JM, Meerbaum S, Burger P, et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 2004; 22: 2877 ‐ 2884.en_US
dc.identifier.citedreferencePacker RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average‐risk medulloblastoma. J Clin Oncol 2006; 24: 4202 ‐ 4208.en_US
dc.identifier.citedreferenceRutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005; 352: 978 ‐ 986.en_US
dc.identifier.citedreferenceMassimino M, Cohen KJ, Finlay JL. Is there a role for myeloablative chemotherapy with autologous hematopoietic cell rescue in the management of childhood high‐grade astrocytomas? Pediatr Blood Cancer 2010; 54: 641 ‐ 643.en_US
dc.identifier.citedreferenceGilman AL, Jacobsen C, Bunin N, et al. Phase 1 study of tandem high‐dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a pediatric blood and marrow transplant consortium study. Pediatr Blood Cancer 2011; 57: 506 ‐ 513.en_US
dc.identifier.citedreferenceChi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high‐dose methotrexate for young children with newly diagnosed high‐risk disseminated medulloblastoma. J Clin Oncol 2004; 22: 4881 ‐ 4887.en_US
dc.identifier.citedreferenceGajjar A, Chintagumpala M, Ashley D, et al. Risk‐adapted craniospinal radiotherapy followed by high‐dose chemotherapy and stem‐cell rescue in children with newly diagnosed medulloblastoma (St Jude Medullobastoma‐96): long‐term results from a prospective, multicenter trial. Lancet Oncol 2006; 7: 813 ‐ 820.en_US
dc.identifier.citedreferenceSung KW, Yoo KH, Chung EH, et al. Successive double high‐dose chemotherapy with peripheral blood stem cell rescue collected during a single leukapheresis round in patients with high‐risk pediatric solid tumors: a pilot study in a single center. Bone Marrow Transplant 2003; 31: 447 ‐ 452.en_US
dc.identifier.citedreferenceSung KW, Yoo KH, Cho EJ, et al. High‐dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high‐risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer 2007; 48: 408 ‐ 415.en_US
dc.identifier.citedreferenceChildren's Oncology Group. COG‐99701: Carboplatin and vincristine plus radiation therapy followed by adjuvant chemotherapy in treating young patients with newly diagnosed CNS embryonal tumors. 1999. [cited 2012 Jun 20]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00003203en_US
dc.identifier.citedreferenceChildren's Oncology Group. COG‐99703: Chemotherapy plus peripheral stem cell transplantation in treating infants with malignant brain or spinal cord tumors. 1999. [cited 2012 Jun 20]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00003141en_US
dc.identifier.citedreferenceNational Cancer Institute. COG‐ACNS0333: Phase III study of induction therapy comprising vincristine, high‐dose methotrexate, leucovorin calcium, etoposide, cisplatin, and cyclophosphamide followed by 3‐dimensional conformal radiotherapy and high‐dose consolidation therapy comprising carboplatin, thiotepa, and autologous peripheral blood stem cell rescue in pediatric patients with atypical teratoid/rhabdoid tumors of the central nervous system. 2008. [cited 2012 Jun 20]. Available from: http://www.clinicaltrials/gov/ct2/show/NCT00653068en_US
dc.identifier.citedreferenceMoore A, Pinkerton R. Vincristine: can its therapeutic index be enhanced? Pediatr Blood Cancer 2009; 53: 1180 ‐ 1187.en_US
dc.identifier.citedreferenceNational Cancer Institute. Common terminology criteria for adverse events and common toxicity criteria v4.0. 2009. [cited 2012 Jun 20]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010‐06‐14_QuickReference_5x7.pdfCTC‐NCIclassificationen_US
dc.identifier.citedreferenceSaito R, Kumabe T, Sonoda Y, et al. Combination chemotherapy with ifosfamide, cisplatin, and etoposide for medulloblastoma: single‐institute experience and differences in efficacy for subgroups of medulloblastoma. Childs Nerv Syst 2011; 27: 1399 ‐ 1406.en_US
dc.identifier.citedreferenceBarone G, Maurizi P, Tamburrini G, et al. Role of temozolomide in pediatric brain tumors. Childs Nerv Syst 2006; 22: 652 ‐ 661.en_US
dc.identifier.citedreferenceLi J, Hamilton E, Vaugn L, et al. Effectiveness and cost analysis of “just‐in‐time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011; 51: 2175 ‐ 2182.en_US
dc.identifier.citedreferenceCooling L, Hoffmann S, Herrst M, et al. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma. Transfusion 2010; 50: 100 ‐ 119.en_US
dc.identifier.citedreferenceGidron A, Verma A, Doyle M, et al. Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies? Bone Marrow Transplant 2005; 35: 243 ‐ 246.en_US
dc.identifier.citedreferenceSutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society for Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213 ‐ 226.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
trf12574.pdf
Size:
268.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.